Patents by Inventor Pui Leng Loke

Pui Leng Loke has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel compounds for treatment of diseases related to DUX4 expression
    Publication number: 20230271953
    Abstract: The present invention relates to compounds that act as DUX4 repressors, suitable for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: November 27, 2020
    Publication date: August 31, 2023
    Applicant: Facio Intellectual Property B.V.
    Inventors: Pui Leng Loke, Joris Herman De Maeyer, Robert David Matthew Pace, Simon Fletcher Elwood, Gregory Foulkes, Andrew Anighoro, Ainoa Rueda-Zubiaurre, Jonathan Philip Richards, Adam James Davenport, Cristina Lecci, Anthony Paul Dickie, Gerd Schnorrenberg
  • New compounds for treatment of diseases related to DUX4 expression
    Publication number: 20230052017
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: November 27, 2020
    Publication date: February 16, 2023
    Applicant: Facio Intellectual Property B.V.
    Inventors: Pui Leng Loke, Joris Herman De Maeyer, Robert David Matthew Pace, Gregory Foulkes, Ainoa Rueda-Zubiaurre, Simon Fletcher Ellwood, Adam James Davenport, Anthony Paul Dickie, Gerd Schnorrenberg
  • CASEIN KINASE 1 INHIBITORS FOR USE IN THE TREATMENT OF DISEASES RELATED TO DUX4 EXPRESSION SUCH AS MUSCULAR DYSTROPHY AND CANCER
    Publication number: 20220226340
    Abstract: The present invention relates to compounds for the treatment of diseases related to DUX4 expression, such as muscular dystrophies. It also relates to use of such compounds, or to methods of use of such compounds.
    Type: Application
    Filed: June 12, 2020
    Publication date: July 21, 2022
    Applicant: Facio Intellectual Property B.V.
    Inventors: Joris De Maeyer, Marcus Geese, Sebastian Monecke, Rolf Hirsch, Pui Leng Loke
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20210299115
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: May 12, 2021
    Publication date: September 30, 2021
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Heteroaryl inhibitors of PAD4
    Patent number: 11026937
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: June 8, 2021
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Covalent inhibitors of PAD4
    Patent number: 10703741
    Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Grant
    Filed: July 27, 2017
    Date of Patent: July 7, 2020
    Assignee: Padlock Therapeutics, Inc.
    Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristina Lecci, Heather Tye
  • HETEROARYL INHIBITORS OF PAD4
    Publication number: 20190358216
    Abstract: The present invention provides compounds useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: September 11, 2017
    Publication date: November 28, 2019
    Inventors: Rajesh Devraj, Gnanasambandam Kumaravel, Cristina Lecci, Pui Leng Loke, Mirco Meniconi, Nathaniel Julius Thomas Monck, Carl Leslie North, Mark Peter Ridgill, Heather Tye
  • Bicyclic tetrahydrothiazepine derivatives useful for the treatment of neoplastic and/or infectious diseases
    Patent number: 10472341
    Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.
    Type: Grant
    Filed: February 29, 2016
    Date of Patent: November 12, 2019
    Assignees: APEIRON BIOLOGICS AG, EVOTEC SE
    Inventors: Monika Ermann, Guenther Lametschwandtner, Patricia Leonie Amouzegh, Russell Stuart Craft, Thomas Hanke, Timothy Robin James, Severine Danielle Jones, Hans Loibner, Pui Leng Loke, Ina Sternberger, Anton Stuetz, Roland Wehr, Mark Whittaker
  • COVALENT INHIBITORS OF PAD4
    Publication number: 20190276432
    Abstract: The present invention provides compounds of formula I useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders.
    Type: Application
    Filed: July 27, 2017
    Publication date: September 12, 2019
    Inventors: Edward Jean Beaumont, Rajesh Devraj, Philip Stephen Kerry, Gnanasambandam Kumaravel, Pui Leng Loke, Mirco Meniconi, Jordan John Palfrey, Carl North, Cristine Lecci, Heather Tye
  • Substituted benzo[b][1,4]oxazines and pyrido[3,2-b][1,4]oxazines as modulators of tumor necrosis factor activity
    Patent number: 10287299
    Abstract: A series of substituted 3,4-dihydro-2H-.1,4-benzoxazin-3-one derivatives, and analogs thereof, being potent modulators of human TNFa activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neuradegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Grant
    Filed: June 7, 2016
    Date of Patent: May 14, 2019
    Assignee: UCB Biopharma SPRL
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • BICYCLIC TETRAHYDROTHIAZEPINE DERIVATIVES USEFUL FOR THE TREATMENT OF NEOPLASTIC AND/OR INFECTIOUS DISEASES
    Publication number: 20180170888
    Abstract: The present invention relates to bicyclic tetrahydrothiazepine of formula (I), wherein R1 to R3, X1, X2 and R18 have the meaning as indicated in the description and claims. The invention further relates to pharmaceutical compositions comprising such compounds as well as their use as medicaments, especially in methods for the treatment or prevention of a neoplastic and/or infectious disease and in vitro methods.
    Type: Application
    Filed: February 29, 2016
    Publication date: June 21, 2018
    Inventors: Monika ERMANN, Guenther LAMETSCHWANDTNER, Patricia Leonie AMOUZEGH, Russell Stuart CRAFT, Thomas HANKE, Timothy Robin JAMES, Severine Danielle JONES, Hans LOIBNER, Pui Leng LOKE, Ina STERNBERGER, Anton STUETZ, Roland WEHR, Mark WHITTAKER
  • Benzoxazinone Derivatives and Analogues Thereof as Modulators of TNF Activity
    Publication number: 20180134728
    Abstract: A series of substituted 3,4-di-hydro-2H-.1,4-benzoxazin-3-one derivatives, and analogues thereof, being potent modulators of human TNF? activity, are accordingly of benefit in the treatment and/or prevention of various human ailments, including autoimmune and inflammatory disorders; neurological and neurodegenerative disorders; pain and nociceptive disorders; cardiovascular disorders; metabolic disorders; ocular disorders; and oncological disorders.
    Type: Application
    Filed: June 7, 2016
    Publication date: May 17, 2018
    Inventors: Gareth Neil Brace, Prafulkumar Tulshibhai Chovatia, Gregory Foulkes, James Andrew Johnson, Severine Danielle Jones, Boris Kroeplien, Fabien Claude Lecomte, Pui Leng Loke, Martin Alexander Lowe, Ajay Mandal, Timothy John Norman, Christopher Francis Palmer, Yolanda Pérez-Fuertes, John Robert Porter, Donald Smyth, Giancarlo Trani, Muhammed Uddin, Zhaoning Zhu
  • Heterocyclic compounds as inhibitors of leukotriene production
    Patent number: 9174980
    Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R7, A and HET are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: January 29, 2013
    Date of Patent: November 3, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Zhidong Chen, Jonathon Alan Dines, Ho Yin Lo, Pui Leng Loke, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
  • Biarylamide inhibitors of leukotriene production
    Patent number: 9073895
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein A, B, C, R1a, R1b, R2, R3, R4a and R4b are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: December 14, 2011
    Date of Patent: July 7, 2015
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Angela Berry, Zhidong Chen, Stephane De Lombaert, Michel Jose Emmanuel, Pui Leng Loke, Chuk Chui Man, Tina Marie Morwick, Hidenori Takahashi
  • 6,5-Heterocyclic Propargylic Alcohol Compounds and Uses Therefor
    Publication number: 20150038460
    Abstract: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Application
    Filed: October 16, 2014
    Publication date: February 5, 2015
    Applicant: Genentech, Inc.
    Inventors: Steven Staben, Jianwen Feng, Pui Leng Loke, Christian A.G.N. Montalbetti
  • 6,5-heterocyclic propargylic alcohol compounds and uses therefor
    Patent number: 8901313
    Abstract: The invention relates to novel compounds of Formula I: wherein A, Y, R1, R2 and the subscript b each has the meaning as described herein and compounds of Formula I, and stereoisomers, geometric isomers, tautomers, solvates, metabolites, isotopes, pharmaceutically acceptable salts, or prodrugs thereof. Compounds of Formula I and pharmaceutical compositions thereof are useful in the treatment of disease and disorders in which undesired or over-activation of NF-kB signaling is observed.
    Type: Grant
    Filed: March 15, 2012
    Date of Patent: December 2, 2014
    Assignee: Genentech, Inc.
    Inventors: Steven Staben, Jianwen Feng, Pui Leng Loke, Christian A. G. N. Montalbetti
  • Benzimidazole inhibitors of leukotriene production
    Patent number: 8829200
    Abstract: The present invention relates to compounds of formula (IA) and (IB): and pharmaceutically acceptable salts thereof, wherein R1-R7 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: October 26, 2011
    Date of Patent: September 9, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Zhidong Chen, Stephane De Lombaert, Jonathon Alan Dines, Weimin Liu, Ho Yin Lo, Pui Leng Loke
  • Oxadiazole inhibitors of leukotriene production
    Patent number: 8658661
    Abstract: The present invention relates to compound of formula (I): or pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: August 12, 2011
    Date of Patent: February 25, 2014
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Todd Bosanac, Zhidong Chen, Stephane De Lombaert, John D. Huber, Ho Yin Lo, Pui Leng Loke, Weimin Liu, Tina Marie Morwick, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell
  • Serotonin 5-HT2B receptor inhibitors
    Patent number: 8609696
    Abstract: Disclosed are Serotonin 5-HT2B receptor inhibitors of the formula I. Also disclosed are methods of making and methods of using these compounds.
    Type: Grant
    Filed: December 14, 2009
    Date of Patent: December 17, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Derek Cogan, Neil Moss, Christopher Ronald Sarko, Samantha Jayne Bamford, Pui Leng Loke, Heather Tye, Mark Whittaker
  • Oxadiazole inhibitors of leukotriene production
    Patent number: 8580829
    Abstract: The present invention relates to compounds of formula (I): and pharmaceutically acceptable salts thereof, wherein R1-R5 are as defined herein. The invention also relates to pharmaceutical compositions comprising these compounds, methods of using these compounds in the treatment of various diseases and disorders, processes for preparing these compounds and intermediates useful in these processes.
    Type: Grant
    Filed: August 23, 2011
    Date of Patent: November 12, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Alessandra Bartolozzi, Todd Bosanac, Zhidong Chen, Stephane De Lombaert, Jonathon Alan Dines, John D. Huber, Weimin Liu, Ho Yin Lo, Pui Leng Loke, Tina Marie Morwick, Peter Allen Nemoto, Alan Olague, Doris Riether, Heather Tye, Lifen Wu, Renee M. Zindell